Ad
related to: recent news on crispr stocks live chart
Search results
Results from the WOW.Com Content Network
As of the most recent quarter, Q3, it reported having around $1.9 billion in cash, equivalents, and short-term investments, and just $402 million in trailing-12-month operating expenses.
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
After the FDA put the company's gene-editing product candidate for sickle cell disease on hold, bargain hunters may want to scoop up some shares. Here's why.
See the 10 stocks » *Stock Advisor returns as of May 13, 2024. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics ...
Science & Tech. Shopping. Sports
For premium support please call: 800-290-4726 more ways to reach us
CRISPR Therapeutics shares have crushed the market since its IPO, delivering an exceptional compound annual growth rate (CAGR) of 20.1%. A lot has changed since then.
Ad
related to: recent news on crispr stocks live chart